Best leukemia therapy may depend on patient age
Older patients may not respond as well as younger persons to conventional therapies for chronic lymphocytic leukemia, a new study indicates.
Diagnosis & Disease Information
Pomalidomide extends survival in multiple myeloma
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
Study drug makes marrow transplant possible in relapsed leukemia
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
December 2012 Briefing – Hematology & Oncology
A round-up of some of the top developments in hematology and oncology in December 2012.
Ibrutinib appears safe, effective against chronic lymphocytic leukemia
Ibrutinib, which targets the Bruton’s tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
Anticancer agent reduces complications after stem-cell transplant
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
ONS Connections: Reliable biomarker for central nervous system tissue injury during pediatric leukemia treatment
During the post-induction phase of treatment for childhood acute lymphoblastic leukemia (ALL), F2 isoprostanes significantly increase, allowing central nervous system (CNS) tissue injury to be monitored.
Higher rates of chronic GVHD seen with peripheral blood stem cell transplants from unrelated donors
Among patients who receive either peripheral blood stem cells (PBMCs) or bone marrow from unrelated donors, the incidence of overall chronic graft-versus-host-disease (GVHD; 53%) is higher in those who received PBMCs than in those who received bone marrow stem cells (40%).
New tool determines “readiness to die” of leukemia cells
A novel method has been developed to determine how ready acute myeloid leukemia (AML) cells are to die. This discovery may help to more effectively choose treatment options for patient with AML.
Children with acute myeloid leukemia benefit from improved diagnostic test
Flow cytometry has been identified as better for checking for minimal residual disease than two other widely used methods to predict patient survival.
- Loading...
Loading...
Loading... 
Loading...